electroCore, Inc.
ECOR4.970USD
-0.025-0.50%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
37.11MMarket Cap
LossP/E TTM
More Details of electroCore, Inc. Company
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
Company Info
Ticker SymbolECOR
Company nameelectroCore, Inc.
IPO dateJun 22, 2018
CEOMr. Daniel S. Goldberger
Number of employees73
Security typeOrdinary Share
Fiscal year-endJun 22
Address200 Forge Way
CityROCKAWAY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07866
Phone19732900097
Websitehttps://www.electrocore.com/
Ticker SymbolECOR
IPO dateJun 22, 2018
CEOMr. Daniel S. Goldberger
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel S. (Dan) Goldberger
Mr. Daniel S. (Dan) Goldberger
Chief Executive Officer, Director
Chief Executive Officer, Director
184.90K
+0.54%
Mr. Thomas M. (Tom) Patton, J.D.
Mr. Thomas M. (Tom) Patton, J.D.
Independent Director
Independent Director
102.78K
+22.69%
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
88.10K
+27.52%
Ms. Patricia Wilber
Ms. Patricia Wilber
Independent Director
Independent Director
72.33K
+35.66%
Ms. Elena Bonfiglioli
Ms. Elena Bonfiglioli
Director
Director
30.55K
--
Dr. Thomas J. Errico, M.D.
Dr. Thomas J. Errico, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Joshua S. Lev
Mr. Joshua S. Lev
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Julie A. Goldstein
Ms. Julie A. Goldstein
Independent Director
Independent Director
--
--
Mr. James C. Theofilos
Mr. James C. Theofilos
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel S. (Dan) Goldberger
Mr. Daniel S. (Dan) Goldberger
Chief Executive Officer, Director
Chief Executive Officer, Director
184.90K
+0.54%
Mr. Thomas M. (Tom) Patton, J.D.
Mr. Thomas M. (Tom) Patton, J.D.
Independent Director
Independent Director
102.78K
+22.69%
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
88.10K
+27.52%
Ms. Patricia Wilber
Ms. Patricia Wilber
Independent Director
Independent Director
72.33K
+35.66%
Ms. Elena Bonfiglioli
Ms. Elena Bonfiglioli
Director
Director
30.55K
--
Dr. Thomas J. Errico, M.D.
Dr. Thomas J. Errico, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Rx gammaCore - Department of Veteran Affairs and Department of Defense
4.72M
70.26%
Truvaga
1.11M
16.46%
Outside the United States
513.00K
7.64%
Rx gammaCore - U.S. Commercial
289.00K
4.30%
TAC-STIM
90.00K
1.34%
By RegionUSD
Name
Revenue
Proportion
United States
6.21M
92.36%
United Kingdom
451.00K
6.71%
Other
47.00K
0.70%
Japan
15.00K
0.22%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Rx gammaCore - Department of Veteran Affairs and Department of Defense
4.72M
70.26%
Truvaga
1.11M
16.46%
Outside the United States
513.00K
7.64%
Rx gammaCore - U.S. Commercial
289.00K
4.30%
TAC-STIM
90.00K
1.34%
Shareholding Stats
Updated: Sun, Sep 14
Updated: Sun, Sep 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Zhang (Tianyi)
9.69%
Theofilos (Charles Steve)
5.86%
Hilve Holdings Ltd
5.70%
Errico (Thomas J.)
4.04%
AWM Investment Company, Inc.
3.56%
Other
71.15%
Shareholders
Shareholders
Proportion
Zhang (Tianyi)
9.69%
Theofilos (Charles Steve)
5.86%
Hilve Holdings Ltd
5.70%
Errico (Thomas J.)
4.04%
AWM Investment Company, Inc.
3.56%
Other
71.15%
Shareholder Types
Shareholders
Proportion
Individual Investor
28.45%
Corporation
9.24%
Investment Advisor
7.58%
Investment Advisor/Hedge Fund
4.99%
Hedge Fund
2.65%
Research Firm
0.25%
Pension Fund
0.04%
Other
46.81%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
83
3.54M
47.26%
+919.62K
2025Q1
79
2.97M
41.24%
+583.46K
2024Q4
81
2.54M
38.89%
+127.67K
2024Q3
72
2.68M
41.45%
+353.98K
2024Q2
75
2.58M
42.20%
+349.71K
2024Q1
80
2.10M
35.02%
-224.03K
2023Q4
78
2.23M
37.11%
+633.96K
2023Q3
84
2.11M
37.42%
+276.86K
2023Q2
89
1.49M
31.36%
-816.60K
2023Q1
91
1.66M
35.08%
-464.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Zhang (Tianyi)
734.64K
9.9%
+734.64K
--
May 15, 2025
Theofilos (Charles Steve)
444.53K
5.99%
--
--
May 12, 2025
Errico (Thomas J.)
246.25K
3.32%
+10.00K
+4.23%
May 12, 2025
AWM Investment Company, Inc.
318.11K
4.29%
+154.97K
+95.00%
Mar 31, 2025
The Vanguard Group, Inc.
232.33K
3.13%
+63.41K
+37.54%
Mar 31, 2025
Goldberger (Daniel S)
142.23K
1.92%
-39.27K
-21.64%
Mar 17, 2025
Renaissance Technologies LLC
178.43K
2.4%
+46.64K
+35.39%
Mar 31, 2025
Happy Holstein Management, LLC
153.17K
2.06%
--
--
May 12, 2025
MAZ Partners, L.P.
115.52K
1.56%
-156.44K
-57.52%
May 13, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 14, 2023
Merger
15→1
Feb 14, 2023
Merger
15→1
Feb 14, 2023
Merger
15→1
Feb 14, 2023
Merger
15→1
Date
Type
Ratio
Feb 14, 2023
Merger
15→1
Feb 14, 2023
Merger
15→1
Feb 14, 2023
Merger
15→1
Feb 14, 2023
Merger
15→1
